Issues

The novel fentanyl-analog “Acrylofentanyl” impairs motor, sensorimotor and cardiovascular functions in mice.

S. Bilel, R. Arfè, M. Tirri, C. Trapella, P. Frisoni, M. Neri, M. Marti

Vol. 2 (No.1) 2020 April
Post-it In Pharmacology,
doi: 10.36118/pharmadvances.01.2020.14

Synthetic opioids are a large class of new psychoactive substances (NPS) mostly consisting of analogs of fentanyl (Fen) that have caused numerous overdose and fatalities worldwide. In 2016 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has reported a total of 130 deaths caused by a new psychoactive substance called “Acrylofentanyl” in United States and Europe. Acrylofentanyl (AcrylF) was spreading online as a research chemical and was mostly sold in a powder or nasal
spray forms. It is a potent NPS that is being used and abused causing more than 21 intoxications and 47 deaths in Europe within a relatively short time period. The aim of the present study was to compare the acute effects evoked by AcrylF, Fen and morphine
(mor) on motor, sensorimotor and cardio-respiratory changes in mice. To better understand the pharmacological action of AcrylF, we used naloxone as opioid receptor antagonist.

Full text PDF

Table of Content: Vol. 2 (No.1) 2020 April

  1. Official Statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary

    G. Trifirò 1,2, L. Berrino 3, M. Del Re 4, R. Bernardini 5, C. Chiamulera 6, A. D’Avolio 7, F. Scaglione 8, A. Capuano 9, E. Clementi 10, R. Danesi 4, L. Pani 11, A. Catapano 12, G. Racagni 12, on behalf of the Section of Clinical Pharmacology of Italian Society of Pharmacology
    Letter to the Editor, 1-5
    doi: 10.36118/pharmadvances.01.2020.01
    Full text PDF

  2. Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary

    A. Capuano 1, F. Scaglione 2, L. Berrino 3, M. Del Re 4, R. Bernardini 5, C. Chiamulera 6, A. D’Avolio 7, G. Trifirò 8,9, E. Clementi 10, R. Danesi 4, L. Pani 11, G. Racagni 12 on behalf of the section of Clinical Pharmacology of Italian Society of Pharmacology
    Letter to the Editor, 6-10
    doi: 10.36118/pharmadvances.01.2020.03
    Full text PDF

  3. Angiotensin-converting enzyme-2 (ACE2): New opportunity or red herring?

    M. Vicenzi 1,2, A. Corsini 3,4, M. Ruscica 3
    Short Article, 11-13
    doi: 10.36118/pharmadvances.01.2020.05
    Full text PDF

  4. The contribution of the clinical laboratory to the new medicine paradigm

    L. Mariani, D. Pedrazzini
    Research Article, 14-18
    doi: 10.36118/pharmadvances.01.2020.06
    Full text PDF

  5. Independent Research in Italy

    G. Corbellini
    Opinion Paper, 19-30
    doi: 10.36118/pharmadvances.01.2020.07
    Full text PDF

  6. Treatment of chronic pain in Italy: therapeutic appropriacy of opioids and fear of addiction. The situation in Italy vs. USA

    D. Fornasari 1, G. Gerra 2, S. Maione 3, G. Mannaioni 4, A. Mugelli 5, D. Parolaro 6, P. Romualdi 7, P. Sacerdote 8
    Research Article, 31-40
    doi: 10.36118/pharmadvances.01.2020.08
    Full text PDF

  7. Herb and spice mediated interactions in oncologic patients treated with chemotherapy

    F. Turco, A. Elio Sprio, I. Bertaggia, T. Armando, S. Storto, S. Allegra, S. De Francia, M. V. Mussa
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.10
    Full text PDF

  8. Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy

    N. Lombardi, G. Crescioli, A. Bettiol, M. Tuccori, M Rossi, R. Bonaiuti, C. Ravaldi, M. Levi, A. Mugelli, S. Ricci, F. Lippi, C. Azzari, P. Bonanni, A. Vannacci
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.11
    Full text PDF

  9. Factors influencing the antiplatelet therapy in patients requiring vascular surgery

    C. Sellitto, V. Conti Valeria, V. Manzo Valentina, T. Iannaccone, M. Costantino, M. Torsiello, G. Di Fiore, G. Accarino, G. Nicolella, G. Corbi, A. Filippelli
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.12
    Full text PDF

  10. Effect of Lactobacillus farciminis supplementation in preventing LPS-induced hippocampal neuroinflammation, in mice

    C. Petrella, G. Strimpakos, F. De Santa, M. Fiore, D. Mora, S. Arioli, S. Farioli-Vecchioli
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.13
    Full text PDF

  11. Role of maternal immune activation in neurodevelopment disorders and possible pharmacological treatment

    F. Aria, A. Mastinu, G. Maccarinelli, M. Premoli, M. Memo, S. A. Bonini
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.15
    Full text PDF

  12. The novel fentanyl-analog “Acrylofentanyl” impairs motor, sensorimotor and cardiovascular functions in mice.

    S. Bilel, R. Arfè, M. Tirri, C. Trapella, P. Frisoni, M. Neri, M. Marti
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.14
    Full text PDF

  13. A new HPLC-UV method compared with HPLC-MS for daptomycin levels in human plasma samples

    G. Luci, F. Cucchiara, M. Lastella, L. Ciofi, R. Danesi, A. Di Paolo
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.16
    Full text PDF

  14. Ultrasonic communication deficits in p50 KO mice and effect of maternal enrichment

    M. Premoli, S. A. Bonini, A. Mastinu, G. Maccarinelli, G. Paiardi, F. Aria, M. Memo
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.17
    Full text PDF
©2024 Edra S.p.A. - P.Iva 08056040960